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Abstract
Background: Failure to regulate the levels of Cdc25A phosphatase during the cell cycle or during a checkpoint
response causes bypass of DNA damage and replication checkpoints resulting in genomic instability and cancer.
During G1 and S and in cellular response to DNA damage, Cdc25A is targeted for degradation through the Skp1-
cullin-b-TrCP (SCF
b-TrCP) complex. This complex binds to the Cdc25A DSG motif which contains serine residues at
positions 82 and 88. Phosphorylation of one or both residues is necessary for the binding and degradation to
occur.
Results: We now show that mutation of serine 88 to phenylalanine, which is a cancer-predisposing polymorphic
variant in humans, leads to early embryonic lethality in mice. The mutant protein retains its phosphatase activity
both in vitro and in cultured cells. It fails to interact with the apoptosis signal-regulating kinase 1 (ASK1), however,
and therefore does not suppress ASK1-mediated apoptosis.
Conclusions: These data suggest that the DSG motif, in addition to its function in Cdc25A-mediated degradation,
plays a role in cell survival during early embyogenesis through suppression of ASK1-mediated apoptosis.
Introduction
When DNA is damaged or when blocks to DNA repli-
cation occur, cells activate an extensive network of sig-
naling pathways that promote cell cycle arrest and DNA
repair [1]. Cell cycle arrest is mediated by checkpoints
in which the activities of cyclin-dependent kinases
(Cdks) are inhibited. Cell cycle arrest presumably pro-
vides time for damage to be repaired and contributes to
the preservation of genomic stability and reduction of
risk for diseases such as cancer. There are two well
established mechanisms by which Cdks are inhibited in
response to DNA damage in mammals. The first
involves activation of the Cdk inhibitor p21
Cip through
activation of p53 [2]. The second is through inactivation
of the Cdc25 family of phosphatases. The most fully
understood mechanism regulating the level of a
phosphatase in this family is the proteasome-mediated
degradation of Cdc25A [3-5].
Cdc25A phosphatase is an essential activator of cell
cycle progression and its expression is tightly regulated at
many levels, including transcriptional activation, reversi-
ble phosphorylation, protein-protein interaction and ubi-
quitin-mediated degradation [6-9]. Ubiquitin-dependent
degradation of Cdc25A is a major mechanism for
damage-induced S-phase checkpoint arrest. Two ubiqui-
tin ligases, the Skp1-cullin-b-TrCP (SCF
b-TrCP) complex
and the anaphase-promoting complex (APC
Cdh1), partici-
pate in Cdc25A turnover. The APC/C proteasome com-
plex helps regulate Cdc25A at the exit of mitosis while
SCF
b-TrCP regulates the abundance of Cdc25A in S phase
and G2 [8,10-13]. When DNA is damaged or when cells
respond to stalled replication forks, ATM and ATR pro-
tein kinases are activated leading to subsequent activation
of Chk1 and Chk2 and to hyperphosphorylation of
Cdc25A. This cascade of events stimulates SCF-mediated
ubiquitinylation of Cdc25A and its proteolysis [3,5], con-
tributing to cell cycle arrest. Failure to regulate Cdc25A
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enhanced DNA damage [3-5,14,15]. Overexpression of
Cdc25A, which frequently occurs in multiple tumor
types [16], leads to accelerated entry of cells into S-phase
[17] and mitosis [3].
The ubiquitinylation-mediated degradation of Cdc25A
is associated with phosphorylation of Cdc25A at two
residues within the b-TrCP docking site (DSG motif).
The DSG docking site of Cdc25A is comprised of ser-
ines 79, 82 and 88, and the absence of their phosphory-
lation is sufficient to abolish b-TrCP binding and
interfere with Cdc25A degradation [10]. Several kinases
have been reported to phosphorylate the DSG motif and
to target Cdc25A for SCF
b-TrCP-mediated degradation
[18-20]. The NIMA related kinase 11 (NEK11) has been
identified as a kinase that specifically phosphorylates
Cdc25A on serines 82 and 88 in cultured cells. This
phosphorylation is important for subsequent ubiquitiny-
lation and proteasome-mediated degradation [19]. The
existence of an S88F polymorphic variant in humans
[21] that elevates the risk for cancer [22] underscores
the importance of serine 88 in cell function, behavior
and disease. Its importance appears to have been con-
served in evolution since the same serine to phenylala-
nine mutation in C. elegans at a serine equivalent to
human serine 88 is a gain of function mutation that
causes deregulated intestinal cell hyper-proliferation and
hyperplasia [23].
To better understand the significance of Cdc25A
p h o s p h o r y l a t i o nw i t h i nt h eD S Gd o m a i ni nc e l lc y c l e
regulation and DNA damage response, we generated a
knock-in mouse model with a substitution of phenylala-
nine for serine at residue 88. The expectation was that
cells from mice harboring this Cdc25A variant would be
less susceptible to SCF
b-TrCP-mediated degradation.
Inhibition of Cdc25A degradation in turn should lead to
its accumulation, accompanied by bypass of DNA
damage and replication checkpoints, enhanced DNA
damage and increased risk of cancer. In the mouse, we
find that this mutation, when homozygous, produces
early fetal lethality, indicating that the Cdc25A DSG
motif and serine 88 phosphorylation may also have a
role in early embryogenesis. Homozygous mutant
embryos that persist display an altered morphology with
extensive cellular degeneration and die at or prior to
embryonic day 3.5. Circular dichroism (CD) studies
revealed that the S88F substitution in Cdc25A protein
had no major effect on protein secondary structure that
would account for the observed phenotype. The mutant
protein retains phosphatase activity but, unlike the wild-
type Cdc25A, the S88F mutant fails to interact with the
apoptosis signal-regulating kinase-1 (ASK1) facilitating
apoptosis mediated by ASK1. These data demonstrate
that the DSG domain of Cdc25A has a role in cell
survival during early embryogenesis that is separate
from its role in Cdc25A ubiquitin-mediated degradation
in response to DNA damage.
Results
Serines 82 and 88 are required for efficient degradation
of Cdc25A following DNA damage
To confirm the role of the DSG domain in Cdc25A
degradation following DNA damage, cDNA encoding
Cdc25A was subjected to site-directed mutagenesis to
replace serine residues 82 and 88 with an alanine either
individually or together. The degree to which wildtype
or mutant Cdc25A was degraded was assessed following
transfection of HEK-293 cells and treatment with the
radiomimetic etoposide (Figure 1A). When both serine
residues were replaced with an alanine, Cdc25A protein
was rendered fully resistant to SCF
b-TrCP-mediated
degradation following etoposide treatment. Substitution
of either serine 82 or 88 to alanine individually was suf-
ficient to confer partial resistance to degradation of
Cdc25A following DNA damage (Figure 1A). Substitu-
tion of serine 88 to phenylalanine also rendered Cdc25A
protein partially resistant to degradation following treat-
ment with etoposide (Figure 1B). The half-life of
Cdc25A wild type and S88F mutant proteins in the
absence of treatment with a DNA damaging agent was
also investigated. Cells were pretreated with cyclohexi-
mide to inhibit de novo protein synthesis, and at the
indicated time intervals cells were collected, lysed and
the Cdc25A protein detected used Flag-M2 antibody
(Figure 1C). The half-life of the Cdc25A S88F mutant
protein was found to be higher than the wild type pro-
tein (Figure 1C).
Cdc25A S88F induces early embryonic lethality in mice
To better understand the roles of the Cdc25A DSG
domain in development and oncogenesis, we generated
a Cdc25A-S88F mouse line by standard gene targeting
in embryonic stem cells. A point mutation in exon 3
leading to substitution of serine 88 with phenylalanine
was introduced using a floxed neomycin-resistant gene
cassette. Although heterozygous mice are viable and fer-
tile, no mice homozygous for Cdc25A S88F were born.
Table 1 shows that out of 277 live pups from matings
between heterozygotes, there were no homozygous
mutants (0%) while 23% were wildtype and 77% were
heterozygous for mutant Cdc25A (Table 1, Figure 2A).
To determine when during gestation the embryos die,
embryos were genotyped at days E12.5, E10.5, E7.5,
E5.5, E3.5, E2.5 and E1.5. The latest time at which any
homozygous mutant embryos were detected was at the
blastula stage (E3.5) (Figure 2B and Table 1). Analysis of
embryo morphology indicated that embryos homozy-
gous for the mutant allele die at or before the blastocyst
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stage were homozygous for the mutant allele rather
than the expected 25% (Table 1). The same was true at
the morula stage (E2.5) and essentially at the cleavage
stage (E1.5) where 0% were observed (Table 1). The
d a t as u g g e s tt h a tt h ev a r i a n ta l l e l e ,w h e nh o m o z y g o u s ,
manifests at or before early cleavage.
Expression of Cdc25A S88F is lethal to early embryos and
cultured cells
To confirm that the S88F mutation leads to early
embryonic lethality, we examined the morphology of
early cleavage embryos and morulae that were charac-
terized by PCR as homozygous for the mutant allele.
The example in figure 3A shows that the only S88F
homozygous embryo in the field (marked by an asterisk)
was shrunken with bleb-like protuberances, suggestive
of apoptotic cell death. Wildtype and heterozygous
embryos appeared normal. To assess whether the S88F
mutant protein by itself was sufficient to promote cell
death, HT1080 cells were transfected with plasmids
encoding wildtype Cdc25A, or mutant Cdc25A S88F or
S82A/S82F proteins, and the cells were assayed for cell
survival. A plasmid encoding a GFP-H2B fusion protein
A.
B.
C.
0 60 90 120 180 240 0 60 90 120 180 240 CHX [min]
Cdc25A
Tubulin D D
Cdc25A wt Cdc25A S88F
Figure 1 Cdc25A S82 and S88 are required for full degradation of the protein following DNA damage. HT1080 cells were transfected
with FLAG-Cdc25A-wt, FLAG-Cdc25A-S82A, FLAG-Cdc25A-S88A, FLAG-Cdc25A-S82A/S88A or FLAG-Cdc25A-S88F. A) When cells were treated with
40 μM etoposide for 12 hours, FLAG-Cdc25A-wt was efficiently degraded while mutant Cdc25A S82A and mutant S88A were partially degraded.
The double mutant S82A/S88A was completely resistant to degradation following DNA damage. B) Similar to FLAG-Cdc25A-S88A, FLAG-Cdc25A-
S88F was partially degraded following treatment with etoposide (40 μM) for 12 hours. C) Exponentially growing cells transfected with either
Flag-Cdc25A or Flag-Cdc25A-S88F were treated with cycloheximide (50 μg/mL) alone to block the protein synthesis. At the indicated time
intervals cell samples were collected and Cdc25A expression was detected by western blot using Flag-M2 antibody. a-tubulin levels are shown
as loading controls. Both Flag-M2 and a-tubulin monoclinal antibodies were purchased from Sigma Aldrich.
Table 1 Genotype distribution in the pups and embryos
from Cdc25A heterozygous crosses
N Age (day) +/+ +/- -/-
277 Pups <22 64 (23) 213 (77) 0
19 e12.5 2 (11) 17 (89) 0
45 e3.5 18 (40) 24 (53) 3 (7)
35 e2.5 13 (37) 20 (57) 2 (6)
93 e1.5 47 (51) 46 (49) 0
Expected (25) (50) (25)
All parents were +/-. N represents the total number of pups or embryos of
each age. The numbers in parentheses indicate the percentage of pups or
embryos of a given genotype based on the total number of that age.
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and Cdc25A S82A/S88F led to rapid cell shrinkage and
rounding, similar to what was seen in homozygous
mutant embryos. Cell death occurred within 16 hours
post transfection (Figure 3B). In contrast, transfection
with plasmids encoding Cdc25A wildtype and GFP-H2B
did not display any characteristics of cell death. Annexin
V staining at 16 hours post transfection showed that
Cdc25A mutants underwent cell death by apoptosis
(Figure 3C).
The S88F substitution confers only subtle conformational
changes on Cdc25A
One concern is that the S88F substitution causes a major
conformational change in the protein that eliminates its
phosphatase activity, which is essential for cell cycle
progression. To determine whether this substitution
significantly alters its secondary structure, Cdc25A-wt
WT
T
WT
T
A.
B.
Figure 2 Mutation of serine 88 to phenylalanine in Cdc25A
induces early embryonic lethality in mice. A) Heterozygous
mutant mice carrying a serine 88 to phenylalanine mutation were
mated and the resulting pups were genotyped. No homozygous
mutant mice were obtained in the progeny. B) Further analysis
shows that the earliest live homozygous embryos were obtained at
the blastocyst stage (day E3.5).
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Figure 3 Cells and embryos expressing serine 88 to phenylalanine mutation undergo cell death. A) Homozygous embryos for the S88F
mutation at day E3.5 appeared blebby and shrunken, indicative of cell death. An increased magnification of mutant cells undergoing apoptosis
is shown. B) HT1080 cells transfected with GFP-Cdc25A-wt, GFP-Cdc25A-S88F, GFP-Cdc25-S88F/S82A or GFP-H2B control show that GFP-Cdc25A-
S88F transfected cells round up and undergo cell death within 16 to 18 hours post transfection. C) Annexin V staining of HT1080 cells
transfected with the same constructs as in B. The data from two independent experiments are shown.
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Page 4 of 9and Cdc25A S88F were compared by far-UV circular
dichroism (CD). The CD spectra of the two proteins
were similar, although they revealed small but significant
differences (Figure 4). The similarity of the curves and
the comparable secondary structure of the two samples
suggest that the serine to phenylalanine substitution does
not lead to large-scale structural changes. Deconvolution
of the data suggests a transition to a slightly more b-
strand-rich secondary structure content in the mutant
protein (Table 2).
Cdc25A S88F retains phosphatase activity in vitro and in
cultured cells
To directly assess the activity of the S88F variant, the
phosphatase activities of Cdc25A S88F and wildtype
Cdc25A were compared in vitro and in cultured cells.
To measure relative phosphatase activities in vitro,t h e
activities of wildtype Cdc25A, Cdc25A S88F and a
Cdc25A S88A mutant were assayed by hydrolysis of 4-
nitrophenol phosphate (pNPP). The phosphatase activity
of Cdc25A S88F mutant is similar to that of wildtype
Cdc25A and Cdc25A S88A, indicating that the serine to
phenylalanine substitution does not inactivate Cdc25A
phosphatase activity in vitro (Figure 5A). To confirm
that Cdc25A S88F retains its phosphatase activity, cells
were transfected with cDNAs encoding either wildtype
Cdc25A or Cdc25A S88F and the level of Cdk1 (cdc2)
dephosphorylation was monitored by assessing the level
of phosphorylated (Y15) Cdk1, a key target of Cdc25
phosphatases. The level of Y15 phosphorylation was
reduced following cell transfection with either Cdc25A-
wt or Cdc25A S88F mutant compared with a GFP-H2B
control, indicating that Cdc25A S88F mutant retains its
phosphatase activity in cultured cells (figure 5B).
Cdc25A S88F loses its interaction with ASK1 and fails to
suppress the stress-inducible ASK1-mediated apoptotic
pathway
Cdc25A physically interacts with ASK1 protein. When
Cdc25A is expressed at elevated levels, it suppresses
stress-induced activation of ASK1 and downstream
kinases [24]. ASK1 mediates the activation of the p38
mitogen-activated protein kinase (MAPK) and the c-
Jun NH2-terminal protein kinase-stress-activated pro-
tein kinase (JNK/SAPK) following various cellular
stresses (Figure 6A) leading to cell death by apoptosis.
Since Cdc25A S88F induces cell death of very early
embryos and of HT1080 cells after transfection, we
tested its ability to suppress ASK1 activity following
treatment with a DNA-damaging agent. Human
HEK293 cells were transfected with a FLAG vector
control plasmid, or plasmids encoding FLAG-Cdc25A-
wt or FLAG-Cdc25A S88F, followed by treatment with
etoposide (40 μM) for 12 hours. Cell lysates were then
probed for immediate targets of ASK-1 mainly SEK
and MKK3 as well as their downstream targets, includ-
ing JNK and caspase 3. Transfected Cdc25A-wt sup-
pressed ASK1 activity as indicated by reduced levels of
SEK, MKK3, JNK and caspase 3 (Figure 6B). Cells
transfected with Cdc25A S88F cDNA, however, did
not suppress ASK1 activity and consequently expres-
sion of downstream targets was unaffected. Failure to
suppress ASK1 activity translates into activation of
apoptosis-mediated cell death. Further analysis showed
that Cdc25A S88F interacts poorly or not at all with
ASK1 as indicated by its inability to co-immunopreci-
pitate with the mutant form of Cdc25A (Figure 6C).
While FLAG-Cdc25A-wt co-immunoprecipitated with
ASK1 from lysates of cells treated with etoposide,
FLAG-Cdc25A-S88F failed to do so. These data may
explain in part the increased cell death observed in
cells that overexpress Cdc25A S88F and in mouse
embryos homozygous for the mutant allele.
Discussion
Cdc25A protein levels are tightly regulated by multiple,
apparently redundant, mechanisms. The importance of
its tight regulation is underscored by the observation
that defects in maintaining steady state levels of Cdc25A
translate into increased cell proliferation that can lead
to cancer. Indeed, Cdc25A is frequently overexpressed
in multiple types of cancer [16]. Ubiquitin-dependent
Figure 4 Comparison of Cdc25A-WT and Cdc25A S88F mutant
secondary structures. The secondary structure content of Cdc25A-
wt and the S88F mutant were compared by far-UV circular
dichroism (CD). The CD spectra of the two proteins were similar,
although they revealed small but significant differences.
Table 2 Deconvolution of Cdc25A far-UV CD spectra
using CDSSTR
Sample Helix Strand Turns Coil Total NRMSD
Cdc25A-wt 8% 34% 23% 34% 99% 0.106
Cdc25A S88F 6% 40% 22% 31% 99% 0.107
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Page 5 of 9degradation of Cdc25A is a major effector of the DNA-
damage-induced S-phase checkpoint. Ubiquitinylation is
mediated by the SCF
b-TrCP complex which binds to a
DSG consensus sequence in Cdc25A that is dependent
on phosphorylation of serines 82 and 88 within the
DSG motif [10,12].
To begin to dissect the functions of Cdc25A and to
better understand the role of ubiquitinylation and degra-
dation in Cdc25A function, we have generated a knock-
in mouse (S88F) in which serine 88, one of two key
serine residues in the DSG domain, is substituted with a
phenylalanine. This serine residue is important for
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HT1080 cells were transfected with GFP-Cdc25A-WT, GFP-Cdc25A-S88F or GFP-H2B control; 12 hours post transfection, lysates from the
transfected cells were assayed for Cdc2-Y15 phosphorylation. Cells equally transfected with either wildtype or mutant Cdc25A show similar levels
of Y15 phosphorylation 12 hours post transfection. Anti-GFP antibody (a mixture of two monoclonal antibodies) was purchased from Roche
Applied Sciences. Cdc2 and Cdc2-Y15 antibodies were purchased from Santa Cruz Biotech. (Santa Cruz, CA).
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Figure 6 Loss of interaction between Cdc25A S88F mutant and ASK1. A) A schematic representation showing ASK1/Cdc25A interaction
leading to suppression of the ASK1 apoptotic pathway. B) Suppression of the ASK1-mediated apoptotic downstream effectors by overexpression
of Cdc25A-wt but not Cdc25A S88F mutant. C) Immunoprecipitation of ASK1 using either FLAG-Cdc25A-WT or FLAG-Cdc25A-S88F shows that
S88F mutant fails to interact with ASK1. ASK-1, p-SEK, p-MKK3, p-JNK and Caspase-3 antibodies were all from Santa Cruz Biotech. (Santa Cruz, CA).
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tion of Cdc25A protein. The expectation was that mice
expressing Cdc25A S88F would have increased amounts
of the protein due to a reduction in its degradation and
that cells would undergo unscheduled replication, dis-
p l a yg e n o m i ci n s t a b i l i t ya n de a r l yt u m o ro n s e ti nt h e
progeny. No mice that were homozygous for Cdc25A
S 8 8 F ,h o w e v e r ,w e r eb o r n .T h eCdc25A
-/- mice exhibit
very early embryonic lethality, which is consistent with a
critical Cdc25A function in cell cycle regulation [25].
Analysis of Cdc25A S88F mutant embryos showed that
the latest embryonic stage at which homozygous
embryos were found was the 3.5 day blastocyst. By this
stage, the very few homozygous Cdc25A S88F embryos
that were present, contained cells that had lost their
spherical shape and looked shrunken with blebbed
membranes consistent with an apoptotic phenotype.
The effect of the Cdc25A S88F mutation was apparent
at the morula stage and even at the oocyte stage. The
rapid cell death that ensued raised a concern that the
S88F mutation in Cdc25A produces major conforma-
tional changes in the protein or eliminates its phospha-
tase activity. Analysis of Cdc25A protein structure by
CD and assessment of its phosphatase activity in vivo
and in vitro showed that the mutation has only a very
minor effect on Cdc25A structure and that its activity is
not significantly different than that of wildtype, indicat-
ing that neither a change in protein conformation nor a
change in enzymatic activity accounts for its lethal
phenotype.
Since mutant Cdc25A displays no significant change
in protein conformation or phosphatase activity, it is
most likely that the lethal phenotype is due to an alter-
native Cdc25A function. It is known that Cdc25A is a
transcriptional target of c-Myc and that overabundance
of Cdc25A suppresses apoptotic cell death [26,27].
One pathway to apoptosis in which Cdc25A partici-
pates involves its interaction with the apoptotic protein
ASK1 [24]. When Cdc25A is elevated, it suppresses
stress-induced activation of ASK1 and downstream
kinases [24]. We therefore tested the possibility that
the mutant Cdc25A S88F does not interact with ASK1
and thereby fails to suppress the pro-apoptotic activity
of ASK1, promoting apoptotic cell death in early
embryos and transfected cells. This scenario is sup-
ported by our finding that ectopic expression of wild-
type Cdc25A effectively suppresses the expression of
targets downstream of ASK1 in response to genotoxic
stress while the expression of the mutant protein fails
to efficiently do so. In the uterus, embryos are sub-
jected to high levels of reactive oxygen species as a
result of the hypoxic environment [28]. Failure of the
Cdc25A S88F mutant to suppress ASK1-mediated
apoptosis will activate the downstream effectors lead-
ing to embryonic lethality.
Materials and methods
Generation of Cdc25A S88F mice
Two fragments of Cdc25A genomic DNA were PCR
amplified and cloned in a pBSK-TK vector. The first
fragment (5030 bp) contained a point mutation
GATTC to GATTT (on exon 3) at position 4780. A
neomycin resistance marker flanked by loxP sites
(LoxP-PGK-Neo-LoxP) was included in the intron 3
immediately after the mutation. A second homologous
arm (6715 bp) was cloned after the Neo cassette using
conventional molecular biology techniques. The
sequence of the targeting construct was validated by
direct sequencing. The vector was linearized at a
u n i q u eN o tIs i t ea n de l e c t r o p o r a t e di n t o1 2 9 / S vE S
cells and neomycin-resistant colonies were screened
for correct targeting by Southern blots. Two faithfully
targeted ES cell lines were identified, and both were
injected into the blastocoel of 3.5-day-old blastocysts
which were implanted into the uterus of recipient
mice. Chimeras carrying the targeted allele were identi-
fied, mated with Black Swiss mice, and agouti progeny
were assayed for transmission of the knock-in allele.
Mice that were homozygous for the S88F variant were
crossed with TgN(EIIa-Cre)C79Lmgd mice (Jackson
Laboratories, Bar Harbor, ME) in an FVB/N strain
background. Cre recombinase is selectively expressed
in the germline of the progeny mice so that their off-
spring will retain the targeted allele without the neo
marker but with a single remaining intronic loxP site.
All animal experiments were carried out under proto-
cols approved by the Institutional Animal Care and
U s eC o m m i t t e eo ft h eU n i v e r s i t yo fC i n c i n n a t i .
Protein purification and circular dichroism
GST-tagged Cdc25A-wt and Cdc25A S88F proteins
were purified using a combination of ammonium sulfate
precipitation (65% cut-off), a size exclusion column frac-
tionation, a sulphopropyl (SP) column to separate the
GST tag from Cdc25A protein following GST tag
removal from the fusion protein using PreScission™
Protease (Sigma), and a glutathione affinity column run
according to the manufacturer’s protocol (Sigma). Puri-
fied wildtype and mutant Cdc25A far-UV CD spectra
were measured using an Aviv 215 circular dichroism
spectrometer. Proteins were dialyzed into 10 mM Tris
pH 8.0, 150 mM NaCl, 1% ethylene glycol, and 2 mM
b-mercaptoethanol, and spectra were measured from
260 to 190 nm. Protein concentrations were determined
using the absorbance at 280 nm and a molar extinction
coefficient of 31,860 M
-1cm
-1, as determined by
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ellipticity [θ]u s i n gt h ee q u a t i o n[]
** *
  
10 Cln r
where θ is the measured ellipticity in millidegrees, C is
the concentration in molar units, l is the pathlength in
cm, and nr is the number of residues. Data were ana-
lyzed using CDSSTR [30] in Dichroweb [31] with refer-
ence set 4.
Cdc25A phosphatase assay
The phosphatase activity of Cdc25A was assayed by
hydrolysis of 4-nitrophenol phosphate (pNPP) (Roche
Applied Science, Indianapolis, IN) as described pre-
viously [32] with modifications. GST-Cdc25A-wt and
GST-Cdc25A-S88F mutant were purified from bacteria
and then incubated in phosphatase reaction buffer (50
mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM
DTT, and 20 ng pNPP) for 6-10 h at 37°C. The reaction
was stopped with 5N NaOH. Cdc25A activity was calcu-
lated by measuring the absorbance of p-nitrophenolate
at 410 nm and subtracting the control background
value. Each point is the mean ± SEM of data from two
separate experiments.
Annexin V staining for flow cytometry
Apoptosis was measured using Annexin V-Cy5.5 (Invi-
trogen, Carlsbad, CA) and propidium iodide (PI). Briefly,
harvested cells were washed in phosphate-buffered sal-
ine (PBS) and resuspended in Annexin V binding buffer
(10 mM Hepes pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
Cells (2 × 10
5) were incubated with 5 μl Annexin V-
Cy5.5 and PI (1 mg/ml) for 10 min in the dark at room
temperature and analyzed by flow cytometry.
Immunocytochemistry
NIH3T3 cells were transfected with a GFP-Cdc25A-wt,
a GFP-Cdc25A-S88F or a GFP-H2B control plasmid.
The cells were washed with PBS 16-18 hours post trans-
fection and fixed with 4% paraformaldehyde. Coverslips
were washed with PBS and mounted with Gelmount
(Fisher Scientific, Pittsburgh, PA). Fluorescent green
cells were then visualized with the use of a LSM510
laser scanning confocal or Orca microscope (Zeiss,
Oberkochen, Germany).
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